Shuttle Pharma acquires PSMA-Boron theranostic asset; engages new IR firm

Shuttle Pharmaceuticals Holdings, Inc.

Upfront $10k each and milestone payments up to $40k each to inventors; 3% royalty on net revenues.
PSMA-Boron is a theranostic agent for diagnosis, staging, and therapy of prostate cancer.
Company engaged John Columbia Inc. to supplement existing IR firm Lytham Partners.
Asset purchase agreement executed Jan 30, 2024; inventors assigned all rights to company.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Shuttle Pharmaceuticals Holdings, Inc. entered into Asset Purchase Agreement with Alan Kozikowski and Werner Tueckmantel valued at Payment of $10,000 each upon signing; additional payments of $10,000 each upon receipt of a research (effective 2024-01-30).

Action: entry
Agreement: asset purchase
Counterparty: Alan Kozikowski and Werner Tueckmantel
Value: Payment of $10,000 each upon signing; additional payments of $10,000 each upon receipt of a research
Effective: 2024-01-30

Exact text from the filing

On January 30, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) and an Assignment of Invention Agreement (the “Assignment”) with Alan Kozikowksi and Werner Tueckmantel (together, the “Inventors”) pursuant to which the Inventors assigned all of their rights, title and interest in the invention entitled “PSMA-Boron” (the “Invention”) to the Company.

View on SEC.gov

114 material agreements filed in the last 30 days. Browse all material agreements →

Shuttle Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-004927

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.